Clinical Trial

A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study adopted an open, single-arm, non-randomized, dose-escalation research design, aiming to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetic and immunogenicity characteristics of single and multiple intravenous infusions of DSL101 in patients with Wilson's disease.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-16.
Status change: Not Yet Recruiting → Recruiting 2026-01-15
Trial Details
NCT Number NCT07240896
Lead Sponsor DSciLab Co., Ltd.
Conditions Wilsons Disease
Enrollment 18 participants
Start Date 2025-12-31
Primary Completion 2028-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-01-20